FDA Seeks Input on Drug Repurposing for Unmet Medical Needs
FDA invites comments on drug repurposing to address unmet medical needs, focusing on FDA-approved drugs with limited commercial interest.
- Publisher
- public-inspection.federalregister.gov
- Length
- 11 pages
- File
- 0 B PDF
Download the full 11-page PDF
Free · 0 B · Instant access after email
The FDA is seeking public input on drug repurposing to address unmet medical needs, focusing on FDA-approved drugs with limited commercial interest.
Key Takeaways
- FDA is establishing a public docket for drug repurposing input.
- Focus on FDA-approved drugs with limited commercial interest.
- Input will help refine FDA's drug repurposing strategies.
- Comments can be submitted electronically or in writing.
- Deadline for comments is 30 days post-publication.
What does this document cover?
The document outlines FDA's request for information on drug repurposing, aiming to gather insights on priority disease areas and candidates for repurposing.
Why it matters for pharma teams
This initiative could unlock new therapeutic uses for existing drugs, enhancing treatment options and addressing gaps in current medical therapies.
Frequently Asked Questions
What is drug repurposing?
Drug repurposing refers to finding new uses for FDA-approved drugs based on existing safety and effectiveness data.
How can stakeholders contribute?
Stakeholders can submit comments and information to the FDA through the established public docket.
What is the deadline for submissions?
The deadline for comments is 30 days after the publication of the notice in the Federal Register.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
More whitepapers like this
🔒 Patient Mastering as Enterprise Infrastructure
Effective patient mastering is crucial for healthcare organizations to ensure accurate patient journeys and reliable analytics, impacting strategic decisions and financial outcomes.
🔒 Cigna Medical Coverage Policy: Acupuncture
Cigna's updated policy outlines conditions for acupuncture coverage, including migraine and musculoskeletal pain, effective April 2026.
🔒 Medicare Risk Arrangement and Use and Outcomes Among Physician Groups
At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for beneficiaries.